To improve life during and beyond sedation
Sedana Medical is a pioneer medtech and pharmaceutical company dedicated to make inhaled sedation a standard therapy in intensive care.More about us
Bringing inhaled sedation to intensive care
We are proud to introduce inhaled sedation to intensive care, a paradigm shift in the care of critically ill patients.
Through the strong results obtained in the pivotal study with Sedaconda (isoflurane) and Sedaconda ACD*, we have laid the foundation for inhaled sedation in intensive care.
By this, we have also taken a major step closer to our vision – to make inhaled sedation a standard therapy in intensive care.
*formerly known as AnaConDa
Our vision is for inhaled sedation to be a global standard therapy for patients in intensive care.
To achieve this, we will through clinical research pave the way for a paradigm shift in sedation in the intensive care.
Our research aims at a greater understanding of and increased knowledge about inhaled sedation, leading to medical advances for the benefit of patients in intensive care.
We also believe in working in partnerships – through various initiatives and research projects – that can lead to continued development and meaningful improvement for both patients and the healthcare system.
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General…
Sedana Medical AB (publ) plans to present its interim report for the third quarter 2021 in an audioc…